Slingshot members are tracking this event:

Actinium Pharma (ATNM) Receives Guidance from European Medicines Agency Regarding Phase 3 SIERRA Study Evaluating Iomab-B in Acute Myeloid Leukemia

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 21, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Guidance, European Medicine's Agency, Ema, Phase 3, Sierra, Iomab-b, Acute Myeloid Leukemia